More Data Needed for Neoadjuvant Tx for Bile Duct Cancer More Data Needed for Neoadjuvant Tx for Bile Duct Cancer
In a debate held recently on the use of neoadjuvant therapy for high-risk intrahepatic cholangiocarcinoma, both sides agreed that more research is needed.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 5, 2023 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Bile Duct Cancer: Awareness, Funding Needed to Fight This Silent Killer
MONDAY, March 20, 2023 -- Lawyer, entrepreneur and avid athlete Mark Clements participated in the 2005 St. George Marathon in Utah, but ongoing stomach pains made finishing the event a struggle.“He was having some stomach pain,”... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2023 Category: General Medicine Source Type: news
Mayo Clinic Q and A: What is cholangiocarcinoma and how is it treated?
DEAR MAYO CLINIC: My mother has been experiencing unusual and persistent fatigue, abdominal pain, and jaundice. After undergoing a CT scan, her doctor diagnosed her with cholangiocarcinoma. What is this type of cancer? And what treatment options are available? ANSWER: Cholangiocarcinoma is a rare cancer that develops from the bile ducts, which are slender tubes that carry the digestive fluid bile and connect the liver to the gallbladder and small intestine. The tumor can occur anywhere along… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 21, 2023 Category: Databases & Libraries Source Type: news
Gallbladder & Bile Duct Cancers: Rare, Silent and Deadly. Know the Signs
WEDNESDAY, Feb. 1, 2023 – Bile duct and gallbladder cancers develop in organs deep inside the body, making them difficult to detect.
Knowing the signs of these rare cancers may help with earlier detection.
Gallbladder cancer and bile duct cancer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 1, 2023 Category: General Medicine Source Type: news
Consumer Health: Treating liver cancer
October is Liver Cancer Awareness Month, which makes this a good time to learn more about treating liver cancer. More than 41,000 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed in the U.S. this year, and more than 30,000 people will die of these diseases, according to the American Cancer Society. Liver cancer is cancer that begins in the cells of your liver, which is a football-sized organ in the upper right portion… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 27, 2022 Category: Databases & Libraries Source Type: news
Latest Mesothelioma T-Cell Clinical Trial Moves to Phase II
The most recent T-cell therapy aimed at mesothelioma cancer has advanced to phase II of the clinical trial process, with researchers exploring its effectiveness when combined with an already approved immunotherapy duet.
Investigators are studying the synergistic effect of gavocabtagene autoleucel (gavo-cel) when used with the combination of Opdivo and Yervoy, which was approved by the U.S. Food and Drug Administration in 2020 to treat mesothelioma.
Its earlier phase I results, when used alone, were impressive – 93% of patients experienced tumor regression – raising hopes for a much-needed advancement in mesotheli...
Source: Asbestos and Mesothelioma News - October 17, 2022 Category: Environmental Health Authors: Lynette Zilio Source Type: news
Orphan Drug Designation Given to New Mesothelioma CAR T-Cell Therapy
In early 2023, the world-class Hospital of the University of Pennsylvania will open a groundbreaking clinical trial for mesothelioma patients utilizing a next-generation immunotherapy with a novel delivery platform.
The U.S. Food and Drug Administration cleared the path in September by granting orphan drug designation for SynKIR-110, a CAR T-cell therapy designed to target solid tumors expressing a specific protein typically found in mesothelioma cancer.
By granting the orphan drug designation, the FDA can provide financial incentives such as tax credits for clinical trials and seven years of market exclusivity. It i...
Source: Asbestos and Mesothelioma News - October 5, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news
FDA Approves Futibatinib for Certain Biliary Tract Cancers FDA Approves Futibatinib for Certain Biliary Tract Cancers
The indication is for use in adult patients with previously treated intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 3, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FGFR2 Inhibitor Nabs Speedy Approval for Cholangiocarcinoma
(MedPage Today) -- The FDA granted accelerated approval to futibatinib (Lytgobi) tablets for treating adults with intrahepatic cholangiocarcinomas that harbor fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
Futibatinib... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 3, 2022 Category: American Health Source Type: news
FDA Approves Lytgobi (futibatinib) for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
Lytgobi (pronounced“light-GOH-bee”) delivered an objective response rate of 42% and median duration of response of 9.7 months in the primary analysis of the pivotal clinical trial.
Lytgobi covalently binds to FGFR2 and inhibits the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 30, 2022 Category: Drugs & Pharmacology Source Type: news
FDA grants accelerated approval to futibatinib for cholangiocarcinoma
On September 30, 2022, the Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - September 30, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Incyte Announces FDA Approval of Pemazyre (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
This marks the second indication for Pemazyre, which received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 26, 2022 Category: Drugs & Pharmacology Source Type: news
Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110TM, a KIR-CAR T-cell Immunotherapy Candidate
Company advances towards in-human clinical trials for SynKIRTM platform targeting Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, and Mesothelioma
PHILADELPHIA, Aug. 19, 2022 -- (Healthcare Sales & Marketing Network) -- Verismo Thera... Biopharmaceuticals, Oncology Verismo Therapeutics, KIR-CAR, CAR T-cell therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 19, 2022 Category: Pharmaceuticals Source Type: news
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
HAIP Chemotherapy or Resection for Multifocal Bile Duct Cancer?
(MedPage Today) -- Hepatic arterial infusion pump (HAIP) floxuridine chemotherapy may represent an effective alternative to curative-intent resection in patients with multifocal intrahepatic cholangiocarcinoma who are at risk for surgical complications... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - May 11, 2022 Category: Surgery Source Type: news
